Last edition
News about "Leerink Partners"
Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock
Avidity Biosciences will use the funds, along with existing reserves, to advance late-stage clinical programmes, prepare for potential launches, expand commercial infrastructure, progress its AOC platform, and for general corporate needs.
Leerink Partners | 13/09/2025 | By Dineshwori
LB Pharmaceuticals Seeks 322 Million USD Valuation in Rare Biotech IPO Amid Market Slowdown
LB Pharmaceuticals, a cash-strapped drug developer, is targeting a valuation of up to 322 million USD (approximately 295 million EURO) in its upcoming New York initial public offering, which could become the first significant biotech listing in several months.
Leerink Partners | 09/09/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy